Navigation Links
Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever
Date:11/15/2009

Nutra Pharma has announced its intention to begin the drug registration process in Brazil and Colombia for its over-the-counter pain reliever. The company is currently marketing a similar analgesic, Cobroxin, in the United States for the treatment of moderate to severe (Stage 2) chronic pain.

Plantation, FL (Vocus) November 15, 2009 -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Brazil and Colombia for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.

“Beginning the drug registration process in Brazil and Colombia offers us the opportunity to introduce our over-the-counter pain reliever into countries that have significant portions of their populations suffering from chronic pain, but lack sufficient access to opioid-based analgesics,” explained Dr. Paul Reid, CEO of ReceptoPharm. “We have already begun conversations with potential South American licensees and plan to initiate the drug registration process in both countries as we move into 2010,” he added.

Nutra Pharma introduced a similar pain medicine in the United States in August under the brand Cobroxin. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, is currently available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

“We are excited to begin the drug registration process in Brazil and Colombia, as these two countries make up approximately 60% of the population of South America and represent the most important entry-points for launching our pain reliever into the entire South American market,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma. “While we complete our drug registration in Brazil and Colombia, we plan to continue building our international presence by registering our pain drug in additional countries worldwide,” he concluded.

In September, Nutra Pharma announced its intention to begin drug registration for its pain reliever in Canada and Europe. Given the existing regulatory requirements in these territories, the Company expects to complete these registrations in the near-term.

About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Cobroxin.com

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Announcing plans to begin the drug registration process in Brazil and Colombia should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Contact:
Nutra Pharma Corp.
David Isserman
877-895-5647

# # #

Read the full story at http://www.prweb.com/releases/Nutra_Pharma/OTC_pain_reliever/prweb3210214.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Vivakor Presents at Nutraceutical Event
2. Reportlinker Adds US World Nutraceutical Ingredients Industry
3. RZN Nutraceuticals Receives United States Patent & Trademark Office Notice of Allowance for Proprietary HerbaZorb(TM) Absorption and Delivery System Technology Used in Popular Arthri-Zen Relief(R) and Migra-Zen Relief PLUS(R) Products
4. Star Scientific Files Second Quarter Financial Results; Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and Viability of Active Components for a Non-Nicotine Nutraceutical (CigRx(TM))
5. NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions
6. NutraCea Announces Additions to Management Team; Chief Operating Officer Extends Employment Contract
7. Nutraceutical Reports Fiscal 2009 Q3 Results and Expands Share Repurchase Program
8. HBA X-Ceuticals Conference Explores The Emerging Market of Cosmeceuticals and Nutraceuticals
9. Nutrition 21 Launches New Innovative PRESCRIPTIX(TM) Nutraceuticals Product Line
10. Synutra Annual Report on Form 10-K Includes Going Concern Explanatory Paragraph from Auditor
11. Synutra International, Inc. Sets the Date for its Fourth Quarter and Fiscal Year Earnings Announcement
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever
(Date:5/26/2016)... Diego, CA (PRWEB) , ... May 26, 2016 , ... ... with him running plumbing calls throughout the beach community. His vision to grow the ... affordable rates and ensuring they maintain the highest level of training and customer service. ...
(Date:5/26/2016)... Overland Park, KS (PRWEB) , ... May 26, ... ... to Hypercet, an industry leader in Blood Pressure products . , High ... to mitigate its effects. Left untreated, high blood pressure can lead to heart ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie is a great ... yourself and save. For a limited time only (offer expires May 31, 2016) customers ... than one, by using the promo code "Memorial" at checkout. The more Bunion Booties ...
(Date:5/25/2016)... ... May 25, 2016 , ... “We ... Managing Partner at HealthScape Advisors. “Brad brings significant experience advising healthcare provider clients ... system accelerates with the implementation of MACRA, we believe that continuing to add ...
(Date:5/25/2016)... ... May 25, 2016 , ... Serenity ... produced another video highlighting one of the many supplemental program options offered at ... Taylor, a 5 th Degree Black Belt in the Shorin-ryu style of Karate ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... 25,2016 FDA 510(k) clearance ... platform for urological and surgical applications ... of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) ... the US with the 12 th 510(k) ... (FDA). This new FDA clearance covers Confocal Miniprobes ...
(Date:5/25/2016)... , May 25, 2016 ... Market by Type (3D, 2D, 4D), by Therapeutic Area ... by End User (Medical Device Manufacturers, Hospitals/ Clinics) - ... the global Medical Animation Market for the forecast period ... reach USD 301.3 Million by 2021 from USD 117.3 ...
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient dringenden ... Brustkrebs   QIAGEN N.V. (NASDAQ: ... heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis ... für die Onkologie eingegangen zu sein. Ein erstes ...
Breaking Medicine Technology: